The ERBB system consists of four receptors (ERBB1–4), two of which, ERBB2/HER2 and ERBB3 are non-autonomous ... is required for a computational model to make use of available data and to ...

[1] HER2 is one of four receptors of the EGF receptor family, it differs from the three other receptors of this family, as it does not require ligand binding for activation. The HER2 protein is a ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01, 2008. The article is based primarily on a ...

Researchers from Novacyte Therapeutics Co. Ltd. presented preclinical data for NC-18, a novel HER2-targeting antibody drug conjugate (ADC) being developed for the ...